Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

65.23
+0.56500.87%
Post-market: 64.46-0.7730-1.19%18:26 EDT
Volume:2.30M
Turnover:150.51M
Market Cap:12.61B
PE:172.12
High:66.30
Open:65.95
Low:64.33
Close:64.67
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:1.46
T/O Rate:1.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:1.99
PE(LYR):36.24

Loading ...

Is BioMarin Pharmaceutical (BMRN) Still Below Fair Value After Its Russell Index Additions?

Simply Wall St.
·
Jul 08

Biomarin Pharmaceutical is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Jul 08

Jefferies Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Jul 06

Spruce Biosciences names Agnieszka Jurecka vice president, medical affairs

Reuters
·
Jun 22

H.C. Wainwright Reaffirms Their Hold Rating on BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Jun 22

BioMarin’s IMPALA Study Aims to Boost Palynziq Value With Better Tolerability

TIPRANKS
·
Jun 18

BioMarin Pharmaceutical Presents 3-Year Voxzogo Data, Early BMN 333 Results for Growth Disorder Treatments

MT Newswires Live
·
Jun 16

BioMarin’s Voxzogo and BMN 333 show impact in hypochondroplasia, achondroplasia

TIPRANKS
·
Jun 16

BioMarin says VOXZOGO lifts height SDS 0.72 over three years in hypochondroplasia study at ENDO 2026

Reuters
·
Jun 16

Is VOXZOGO’s Hypochondroplasia Data and Amicus Deal Reshaping the Investment Case for BioMarin (BMRN)?

Simply Wall St.
·
Jun 10

BioMarin shareholders approved 7,650,000-share increase to 2017 equity plan at annual meeting

Reuters
·
Jun 05

A Look At BioMarin Pharmaceutical (BMRN) Valuation After Recent Share Price Strength

Simply Wall St.
·
Jun 04

BioMarin Pharmaceutical (BMRN) Receives a Buy from Guggenheim

TIPRANKS
·
Jun 03

Centene, Deckers and 14 Other 'Dividend Hopefuls' -- Barrons.com

Dow Jones
·
Jun 02

Capricor names Michael Maurer chief commercial officer

Reuters
·
May 29

BioMarin Pharmaceutical (BMRN) Receives a Hold from Stifel Nicolaus

TIPRANKS
·
May 25

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 24

BioMarin Pharmaceutical Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
May 23

BioMarin price target lowered to $111 from $116 at Canaccord

TIPRANKS
·
May 22

BioMarin's drug shows significant growth gains in children in late-stage trial

Reuters
·
May 21